Based on a recent article posted at European Pharmaceutical review, sustainability would be one of the critical elements for pharmaceutical businesses in the next years.
According to CPHI’s Annual Survey 2023 the pharma supply chain is rapidly adopting sustainability targets and indicators.
Most CDMOs are anticipated to employ them within two years. The findings revealed a considerable change from last year’s study, which predicted changes throughout five years.
The latest results at CPHI Barcelona show that 93% of executives consider ‘visibility on supply chain partner’s sustainability record’ ‘extremely important’ or ‘important’.
“The rate of change is increasing rapidly and is expected to be one of the biggest themes for manufacturing in 2024,” said Silvia Forroova, Informa Markets Director of Partnerships & Sustainability.
CPHI’s Annual Survey 2023 Key findings
- 9% of pharma businesses reported ‘no ongoing green manufacturing activities’ according to CPHI Barcelona results.
- 40% of industrial initiative is ‘waste and water reduction programs at 40%.
- 33% of initiatives are related to Process improvement working groups—including green chemistries, metal catalysis, and continuous processing.
- 32% of initiatives are related to manufacturing equipment optimization, such as intelligent energy programs and machine learning for process efficiency and
- 29% of initiatives are related to decarbonizing company supply chains.
- 60% of executives expect innovators to demand CDMOs to include sustainability measures like complete trash recycling, green electricity consumption, low PMI objectives, and green chemistry in their contracts within two years.
- 20% want CDMOs to demonstrate ESG aims in supplier negotiations.
- Only 20% think innovators will base new contract choices only on cost and capabilities.
